KevinMD.com: Social media’s leading physician voice
The KevinMD newsletterReal physician voices, twice a weekFree, and one click to unsubscribe.
Subscribe free →

Does Merck have a “homefield advantage” in the next Vioxx trial?

Does Merck have a “homefield advantage” in the next Vioxx trial?

“In Texas, there’s significant bias against what’s considered an out-of-town evil drug company. But in New Jersey, you actually know people who work at Merck and Pfizer, so it puts a human face on it. It’s not big, bad pharma; it’s my neighbor Joe.”

Share this articleLinkedInFacebookXEmail

Real physician voices, twice a week

Free, and one click to unsubscribe.

No spam. We never share your email.